BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-125@catalystbrief.girapphe.com
DTSTAMP:20261117T181557Z
LAST-MODIFIED:20261117T181557Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Takeda — TDV [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Dengue Tetravalent Vacci
 ne (TDV) in Adults (Age 45 to 60 and >60 to 79 Years).\nSource: https://cl
 inicaltrials.gov/study/NCT06579755\nhttps://catalystbrief.girapphe.com/e/1
 25?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/125?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
